Time to occurrence of cardiac disorders
Figure 6. · Panel A
Panel A 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter S Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A Yimer, Megan Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Blood 144(26) 2706-2717
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis with extended follow-up. Overall, 652 patients received zanubrutinib (n = 327) or ibrutinib (n = 325). At an overall median follow-up of 42.5 months, progression-free survival benefit with zanubrutinib vs ibrutinib was sustained (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.54-0.84), including in patients with del(17p)/TP53 mutation (HR, 0.51; 95% CI, 0.33-0.78) and across multiple sensitivity analyses. Overall response rate remained higher with zanubrutinib compared with ibrutinib (85.6% vs 75.4%); responses deepened over time with complete response/complete response with incomplete bone marrow recovery rates of 11.6% (zanubrutinib) and 7.7% (ibrutinib). Although median overall survival has not been reached in either treatment group, fewer zanubrutinib patients have died than ibrutinib patients (HR, 0.77 [95% CI, 0.55-1.06]). With median exposure time of 41.2 and 37.8 months in zanubrutinib and ibrutinib arms, respectively, the most common nonhematologic adverse events included COVID-19-related infection (46.0% vs 33.3%), diarrhea (18.8% vs 25.6%), upper respiratory tract infection (29.3% vs 19.8%), and hypertension (27.2% vs 25.3%). Cardiac events were lower with zanubrutinib (25.9% vs 35.5%) despite similar rates of hypertension. Incidence of atrial fibrillation/flutter was lower with zanubrutinib vs ibrutinib (7.1% vs 17.0%); no cardiac deaths were reported with zanubrutinib vs 6 cardiac deaths with ibrutinib. This analysis, at 42.5 months median follow-up, demonstrates that zanubrutinib remains more efficacious than ibrutinib with an improved overall safety/tolerability profile. This trial was registered at www.ClinicalTrials.gov as #NCT03734016.
1 个 Figure · 3 个 KM 面板
Time to cardiac disorders and cardiovascular AEs of interest. (A) Time to occurrence of cardiac disorders; based on MedDRA version 26.0 cardiac disorder system organ class. (B) Time to occurrence of atrial fibrillation or flutter. (C) Time to occurrence of hypertension.
Figure 6. · Panel A
Panel A 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6. · Panel B
Panel B 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6. · Panel C
Panel C 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。